Sakurasaku Plus
7097
Timee
215A
Wintest
6721
Heartseed
219A
Raksul
4384
JP Stock MarketDetailed Quotes
4575 CanBas
- 917
- +56+6.50%
20min DelayMarket Closed Dec 13 15:30 JST
17.53BMarket Cap-13.51P/E (Static)
938High883Low632.30KVolume891Open861Pre Close575.09MTurnover151252wk High3.59%Turnover Ratio19.11MShares41152wk Low-67.9EPS TTM16.14BFloat Cap4530Historical HighLossP/E (Static)17.60MShs Float162Historical Low-67.9EPS LYR6.39%Amplitude--Dividend TTM7.06P/B100Lot Size--Div YieldTTM
About CanBas Company
CanBas Co Ltd focuses on the discovery and development of novel oncology drugs targeting the cell cycle. Its product, CBP501 the anticancer drug candidate is a modified synthetic peptide which enhances the efficacy of cisplatin without adding toxicity.
Company Profile
Symbol4575
Company NameCanBas
Founded2000-01-18
MarketTSE Growth
Fiscal Year Ends06-30
Address9 Toriyoko-cho
Zip Code410-0801
Phone055-954-3666
Websitewww.canbas.co.jp
Company Executives
- Name
- Position
- Salary
- Makoto Katozumi
- Chief Financial Officer and Head of Corporate Planning
- --
- Kazuyoshi Sakamoto
- Director and Manager of Administration
- --
- Takumi Kawabe
- Representative Director and President
- --
- Akira Shirakawa
- Independent Director
- --
- Yasuyuki Komiyama
- Independent Director
- --
- Toshio Furuta
- Independent Director
- --